{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Positive : Familiarity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Positive : Overall Comfort"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Positive : Ability to Rest After Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Positive : More Time in the Day for Work/Other Activities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Positive : Eliminated Travel Inconveniences"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Positive : Acceptability of Home Blood Draws"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Positive : Satisfaction with Home Infusion Staff"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Negative : Wait Times"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Patient perceptions of home based anti-neoplastic therapy will be measured through semi-structured interviews.","groups":[{"description":"Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nDaratumumab and Hyaluronidase-fihj: Given SC\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nInterview: Ancillary studies","id":"OG000","title":"Treatment (daratumumab and hyaluronidase-fihj)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Cycle 3 through Cycle 6, days 57-169","title":"Patient Perceptions of Home Based Anti-neoplastic Therapy","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}